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SUMMARY 
BACKGROUND: Lung cancer (LCa) is the most common cancer in both men and 
women, being responsible for more deaths than any other malignancy. It is well known the 
importance of early diagnosis of LCa and personalized therapy according to disease 
genomic characteristics. Thus, discrimination between the LCa subtypes becomes a key 
to reduce the mortality rate because allows for more specific treatments. LCa are broadly 
classified into two groups: small cell lung cancer (SCLC) and non-small cell lung cancer 
(NSCLC), the latter being divided into adenocarcinoma, squamous cell carcinoma (SCC) 
and large cell carcinoma (LCC), among other less frequent subtypes. 
AIMS: The main goal of this dissertation was to evaluate the methylation profile of the 
major LCa subtypes, with a panel of genes previously reported to be hypermethylated in 
LCa: APC, HOXA9, RARβ2, RASSF1A, TFPI2 and SHOX2. In particular, we aimed to 
discriminate adenocarcinoma, the most prevalent subtype, from the other LCa subtypes. 
Moreover, we evaluated the association between the gene-panel methylation levels and 
standard clinicopathological parameters as well as determined the prognostic value of the 
same gene-panel. 
MATERIAL AND METHODS: Methylation levels of APC, RASSF1A, RARβ2, HOXA9, 
SHOX2 and TFPI2 were assessed using real-time quantitative MSP in bisulfite-modified 
DNA extracted from formalin-fixed paraffin embedded tissue samples from 152 LCa and 
22 normal lung parenchyma (NL) from individuals with other neoplasias. Survival analyses 
were conducted to evaluate its prognostic value. 
RESULTS: Methylation levels of APC, HOXA9, RARβ2 and RASSF1A discriminated the 
major subtypes, NSCLC from SCLC (P < 0.001; P = 0.021; P < 0.001; P < 0.001; 
respectively). APC and RASSF1A distinguished SCC and Adenocarcinoma from SCLC (P 
< 0.001; P < 0.001; respectively), whereas. RARβ2 discriminated all subtypes of NSCLC 
from SCLC (Adenocarcinoma vs SCLC, P < 0.001; SCC vs SCLC, P < 0.001; LCC vs 
SCLC, P = 0.036). HOXA9 also differentiated Adenocarcinoma from SCLC (P < 0.001), 
and it was the only gene that discriminated Adenocarcinoma from SCC (P = 0.024).. Low 
APC, HOXA9, RARβ2 and RASSF1A promoter methylation levels associated with poorer 
disease specific survival, although not independently as it was dependent of poor tumor 
differentiation. Low RASSF1A promoter methylation levels also predicted poor disease-
free survival in univariable analysis but due to its association with tumor differentiation, it 
did not retain independent prognostic significance in multivariable analysis. 
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CONCLUSIONS: Assessment of RARβ2 and HOXA9 promoter methylation levels using 
qMSP is able to to discriminate among major LCa subtypes in tissue samples. The clinical 
usefulness of these biomarkers in plasma will be tested in the near future.  
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RESUMO 
 
INTRODUÇÃO: O cancro do pulmão é mais comum tanto em homens como em 
mulheres, sendo, ainda, o principal responsável pela mortalidade associada a cancro. 
Está bem estabelecida a importância de um diagnóstico precoce de cancro do pulmão 
bem como a instituição de terapia personalizada, a qual é realizada de acordo com as 
características da neoplasia. Portanto, descriminar precocemente os principais subtipos 
de cancro de pulmão torna-se determinante para reduzir a taxa de mortalidade, uma vez 
que permite melhor especificar as estratégias terapêuticas. O cancro do pulmão é 
habitualmente classificado em dois grupos: carcinoma de pequenas células e carcinoma 
de não pequenas células. Este último subdivide-se em adenocarcinoma, carcinoma 
epidermoide e carcinoma de grandes células, para além de outros subtipos menos 
expressivos em termos de frequência. 
OBJECTIVOS: O objetivo principal desta dissertação de mestrado foi avaliar os perfis de 
metilação de diferentes subtipos de cancro do pulmão com um painel de genes 
previamente descritos na literatura - APC, HOXA9, RARβ2, RASSF1A, TFPI2 e SHOX2. 
Mais especificamente, pretendeu-se descriminar os adenocarcinomas, que representam 
o subtipo mais prevalente, dos restantes subtipos de cancro do pulmão. Adicionalmente, 
foi analisada a associação entre os níveis de metilação do painel de genes e as 
características clinico-patológicas, bem como o valor prognóstico. 
MATERIAL E MÉTODOS: Os níveis de metilação de APC, RASSF1A, RARβ2, HOXA9, 
SHOX2 e TFPI2 foram determinados através de PCR quantitativo de metilação em tempo 
real, utilizando DNA modificado por bissulfito de sódio extraído de amostras de tecido 
fixado em formol e incluído em parafina de 152 cancros do pulmão e 22 amostras de 
parênquima pulmonar normal proveniente de indivíduos com outras neoplasias. A análise 
de sobrevivência foi realizada para avaliar o valor prognóstico dos genes do painel. 
RESULTADOS: Os níveis de metilação dos genes APC, HOXA9, RARβ2 e RASSF1A 
descriminaram os subtipos principais de cancro de pulmão (P < 0.001; P = 0.021; P < 
0.001; P < 0.001; respetivamente). APC e RASSF1A diferenciaram os carcinomas 
epidermoides e adenocarcinomas dos carcinomas de pequenas células (P < 0.001; P < 
0.001; respetivamente), enquanto que RARβ2 descriminou todos os subtipos 
pertencentes aos carcinomas de não pequenas células dos carcinomas de pequenas 
células (Adenocarcinoma vs Carcinoma de pequenas células, P < 0.001; Carcinoma 
epidermoide vs Carcinoma de pequenas células, P < 0.001; Carcinoma de grandes 
células vs Carcinoma de pequenas células, P = 0.036). HOXA9 também diferenciou os 
adenocarcinomas dos carcinomas de pequenas células (P < 0.001), sendo, ainda, o 
ix 
 
único gene a descriminar os adenocarcinomas dos carcinomas epidermoides (P = 0.024). 
Por outro lado, SHOX2 e TFPI2 não mostraram diferenças estatisticamente significativas 
entre nenhum dos subtipos. Níveis baixos de metilação do promotor dos genes APC, 
HOXA9, RARβ2 e RASSF1A associaram-se a pior sobrevivência específica de doença, 
mas dependente do grau de diferenciação, enquanto que baixos níveis de metilação do 
gene RASSF1A se associaram a pior sobrevivência livre de doença, mas também 
dependente do grau de diferenciação. 
CONCLUSÕES: A avaliação dos níveis de metilação dos promotores dos genes RARβ2 
e HOXA9 podem ser úteis para descriminar os subtipos de cancro do pulmão em 
amostras de tecidos parafinado. A utilidade clínica destes genes como biomarcadores em 
plasma será avaliada num futuro próximo.  
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1. INTRODUCTION 
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1.1 Lung Cancer 
1.1.1 Epidemiology and causes 
Lung cancer (LCa) has been considered the most commonly diagnosed cancer in 
the world for several decades. As the leading cause of cancer related death in the world, 
LCa is currently a public health problem of enormous magnitude1. In 2012, LCa was 
estimated to be the most common cancer worldwide (12.9% of total diagnosed cases) and 
the leading cause of cancer- related deaths worldwide (19.4% of total cancer cases). In 
fact it represents more than one-fifth of all cancer related deaths, which is higher than 
breast, colon and prostate cancer combined (Figure 1). Despite the incidence rate is lower 
in women compared to men, its remains the main cause of death by cancer for both 
genders2.  
 
Figure 1 - (A) Estimated worldwide cancer incidence rates for both genders; (B) Estimated worldwide cancer 
mortality rates for both genders. Adapted from Ferlay, 20123. 
3 
 
Incidence and mortality rates of LCa in Europe are slightly different to those that 
characterize worldwide distribution. Regarding the incidence rate, is the fourth more 
incident, representing 11.9% of total diagnosed cases, more specifically the second more 
frequent in men (15.9%) and the third more common at women (7.4%). In terms of 
mortality it is considered the most frequent cause of cancer related deaths in Europe (one 
fifth of the total), being the most common cause of cancer death in men (26.1%), and the 
third in women (12.7%)4. 
In Portugal, LCa is the fourth most frequent malignant neoplasia and is the second 
most mortal, following closely colorectal cancer (8.5%) 4. 
Importantly in LCa, the mortality rate parallels the incidence rate mainly due to 
persistently low patient survival. Despite the development of clinical diagnosis techniques 
and treatment, the overall 5-year survival rate remains extremely low (10%). This poor 
outcome is attributable not only to the fact that almost two thirds of cases are diagnosed 
at advanced stages but also to the high rate of recurrence after surgical resection 5, 6. 
LCa tends to be most incident in developed countries, especially in North America 
and Europe, and less common in developing countries, particularly in Africa and South 
America1. 
At older age groups, both mortality and incidence rates continue to increase for 
both genders. However the increasing rates are decelerating more in men than in women. 
Regarding younger age groups, the rates of LCa are decreasing, for both genders, being 
more evident in men than women1. 
The hypothesis that women might have a greater LCa risk than men with the same 
smoking habits has been suggested. Nevertheless, several other studies that compared 
the relative risk of a specific degree of smoking history for men and women demonstrate 
very similar risks. Interesting differences in LCa characteristics between men and women 
have been noted. First, women with LCa present a better prognosis than men. Second, 
estrogens may augment lung cancer risk. Third, among never smokers, women have 
higher percentage of adenocarcinomas and higher prevalence of EGFR mutations than 
men. These observations suggest that distinct gender differences in lung carcinogenesis 
might potentially be clinically important1. 
Nonetheless, there are other factors considered to be possible risk factors, such as 
asbestos, pulmonary chronic disease, environmental pollution or family history7. 
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1.1.1.1 Risk Factors 
Several risk factors contribute for development of LCa including tobacco smoking, 
asbestos, radon, environmental pollution or family history7. 
1.1.1.1.1 Cigarettes 
Cigarette smoking is by far the leading cause of LCa8. About 85% of LCa patients 
presents a tobacco-smoking history and approximately 50% were former smokers9. The 
risk increase with duration of smoking and the number of cigarettes smoked daily1. 
Patients with a smoking history of at least 20 to 30 pack-years present a substantially 
increased risk to develop LCa. Smoking cessation is associated with a gradual reduction, 
however it does not reach that of a never smoker.9 Smoking confers an approximately 25-
fold increased risk for lung cancer in current smokers1. Tobacco smoke is characterized 
by a complexity of compounds that promote damage in lung cells and clearly contributes 
to the accumulation of genetic alterations in lung cancer8. Most of lung cancer cases in 
men (85%) and nearly half of lung cancer cases in women are estimated as being the 
consequence of tobacco smoking7. 
Passive exposure to cigarette is another risk factor that contributes to nearly 1% of 
all cases of LCa9. Passive smokers inhale a complex mixture of smoke, which is now 
widely referred to as “environmental tobacco smoke”. Passive smoking is more weakly 
associated with LCa than is active smoking. This fact is due to the lower doses of 
carcinogens received by the nonsmoker compared with the smoker. Marriage to a smoker 
has been associated with about a 20% risk increase and exposure in the workplace has 
been associated with an increased risk of 24% to a twofold increase at the highest levels 
of exposure1. 
1.1.1.1.2 Exposure to Other Carcinogens 
Occupational exposure to lung carcinogens have been estimated to account for 
about 9% to 15% of LCa cases. Cigarette smoking potentiates the effect of some of the 
known occupational lung carcinogens1. Asbestos, is a well-established occupational 
carcinogen which acts synergistically with smoke and increase the risk to LCa. 
Occupational exposure to asbestos leads to an estimated 4-fold higher risk for LCa9. 
Specifically, a person who smokes and has been exposed to asbestos has a greater than 
50-fold elevated risk for LCa than does a nonsmoker with no asbestos exposure1. Radon 
exposure has also been implicated in the development of 5 to 8% of lung cancer cases9. 
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1.1.1.1.3 Family History 
A positive family history of lung cancer is a clinically useful risk indicator1. Patients 
with a family history of early lung cancer (before 60 years old) accounts for an 
approximately 2.5-fold increased risk. Genetic susceptibility may be seen with rare 
autosomal dominant genes that explain only few cases of early-onset LCa. Contrarily, 
common genetic variants or polymorphisms are more likely to affect LCa risk8. 
Nevertheless, as with smoking, not all who are exposed to these environmental 
factors go on to develop lung cancer1. 
1.1.2 Lung Cancer Subtypes 
Lung cancer may present multiple histologic types as classified by conventional 
light microscopy. There are two main histological groups: small cell lung cancer (SCLC) 
comprising approximately 20% of LCa cases and non-small cell lung cancer (NSCLC), 
which represents the remaining lung tumors (Figure 2). Histologically, NSCLC include 
three major histological subtypes: adenocarcinoma – the most prevalent form (40%) –, 
squamous cell carcinoma (25%) and large-cell carcinoma (10%)10. 
 
Figure 2 - Histological patterns of lung cancer. (A) Small cell lung cancer; (B) Adenocarcinoma, (C) 
Squamous cell carcinoma; (D) Large cell carcinoma.  
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1.1.2.1 SCLC 
SCLC is one of the most aggressive and rapidly growing types of LCa. This 
subtype is characterized by a poor prognosis due to a propensity for early hematogenous 
dissemination7. Cigarette smoking has a strong connection with this type of cancer, being 
98% of all SCLC cases caused by tobacco smoke. Clinically and biologically is considered 
different from NSCLC. Pathologic diagnosis can be challenging because of an abundance 
of necrotic tissue but is established by characteristic features such dense sheets of small 
cells with scant cytoplasm, finely granular nuclear chromatin, high degree of mitoses, 
necrosis and inconspicuous or absent nucleoli (Figure 2A)9. SCLC has a dismal 
prognosis, with a 2 year survival rate of only 10% with metastatic disease and a 5 year 
survival rate of approximately of 25% with is no metastatic involvement. Younger age, 
female gender and surgery for limited disease are favorable features. Contrarily, 
continued smoking is a strong adverse prognostic factor. It is frequently identified by chest 
imaging, and more specifically, in lung parenchyma, that may spread along bronchi in a 
subepithelial and radial pattern, also involving lymphatic vessels7. 
1.1.2.2 NSCLC 
1.1.2.2.1 Adenocarcinoma 
In the last two decades, adenocarcinoma incidence has been rising and it is now 
the most predominant histological subtype, surpassing squamous cell cancer9. This might 
be due to the changes in the design and in the characteristics of manufactured cigarettes 
which might have increase the puff volume, causing a shift from more central deposition of 
tobacco smoke to more peripheral deposition. This is particularly relevant since this type 
of LCa usually originate in peripheral airways7. Moreover, malignant lesions in this region 
may be present for a long time before symptoms manifestation, being mostly diagnosed in 
advanced stages. Histologically adenocarcinomas are characterized by glandular 
differentiation with mucin production (Figure 2B)11. Generally, this histological type is 
diagnosed in women, non-smokers and in Asians. However, never-smokers and women 
are favorable prognostic factors. There are several subtypes of adenocarcinoma, 
however, the majority are histologically heterogeneous and thus classified as mixed7. 
Compared with squamous cell, this subtype is prone to develop distant metastasis. 
Invasive adenocarcinoma represents nearly 90% of all cases of adenocarcinoma7, 9. 
1.1.2.2.2 Squamous Cell Carcinoma (SCC) 
Squamous cell carcinoma, also known as epidermoid carcinoma, represents the 
second most incident subtype7. Histologically it is characterized as a malignant epithelial 
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tumor that shows keratinization and/or intercellular bridges (Figure 2C)12. This type of LCa 
grows commonly in central areas around major bronchi in a stratified or pseudo ductal 
arrangement9. Commonly is has a slow development, increasing the probability of finding 
it in early stages compared to other types of LCa. However, SCC has a tendency to be 
locally aggressive, involving adjacent structures through direct invasion. This subtype is 
more common in men and smokers, when compared with other histological subtypes7. 
1.1.2.2.3 Large Cell Carcinoma (LCC) 
 Large cell carcinomas have been classified as poorly differentiated carcinomas 
that lack any squamous or adenocarcinoma differentiation (Figure 2D). Gene expression 
profiling has shown evidence of epithelial-mesenchymal transition as a frequent finding in 
large cell carcinomas, reflecting their poor differentiation compared to other NSCLC. Only 
when additional staining is negative, unclear, or not available the diagnosis of large cell 
carcinoma is made. However, their incidence is decreasing as a reflection of alteration in 
the approach of in pathologists’ diagnostic which is mainly due to the introduction of 
immunohistochemistry for glandular and squamous markers. LCC lesions are typically 
localized on peripheral solid masses that are usually large, circumscribed, commonly with 
necrosis, but rarely with cavitation7. LCC, commonly has a rapid growth associated with a 
vast capacity to spread. This subtype is often associated with an aggressive clinical 
course and poor survival rates, even when it is found in the setting of early-stage 
disease9. Classification as large cell carcinoma requires morphological and 
immunohistochemical exclusion of other tumor types, as both cytological appearances 
can occur in other types of NSCLC7. Since this histologic subtype is often difficult to 
accurately diagnose owing to an abundance of necrotic tissue and poor degree of 
differentiation, diagnosis requires an adequate tissue sampling. Most of LCC patients are 
smokers9. 
1.1.3 Diagnosis 
As LCa symptoms are similar to those of common several disease they are 
sometimes disregarded and the diagnosis is often delayed. There are several symptoms 
connected with the presence of LCa depending on the degree of tumor development11. 
Some symptoms that should raise suspicion of LCa are coughing up blood (hemoptysis), 
chest and bone pain, breathing problems, weakness or loss of sensation in body parts. It 
is imperative, when this symptoms are detected, to determine whether these alterations 
are due LCa or other respiratory disease11, 12. 
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The majority of LCa patients have other tobacco-related cardiopulmonary 
diseases, therefore these overlapping symptoms often result in a late diagnosis of 
malignant disease9. 
Moreover, at diagnosis, only 15% of patients with LCa are asymptomatic. Accurate 
diagnostic characterization of lung cancer is essential, since the status of mediastinal 
nodal metastases is crucial for determining prognosis, assessing resectability, and 
selecting the appropriate treatment strategy for primary LCa9.  
Early stage LCa is often manifested as pulmonary nodules, defined as “rounded 
opacity, well or poorly defined, measuring up to 3 cm in diameter”. Pulmonary nodules 
may often be due to current or prior infection, although they also may be the manifestation 
of early cancer. National Lung Screening Trial (NLST) demonstrated that more than 95% 
of all  detected nodules were false positives and noncancerous9. 
Nowadays, the major detection tools are evaluation of clinical history, 
bronchoscopy (to allow evaluation of the extent of the disease in the tracheobronchial 
tree), blood tests joined with physical exams (to examine the general signs of health), 
chest x-ray (to evaluate the presence and size of tumors or abnormal fluid in the chest), 
computerized topographies (CT) scan (to examine the disease extent or the presence of 
pulmonary nodules) and biopsy (to allow tumor identification). However, the majority of 
diagnosis are made incidentally on a chest radiography9, 12. 
1.1.4 Staging 
When a tumoral mass is detected during diagnosis, LCa staging is essential for 
selection of the most appropriate treatment. Patients are staged according to the TNM 
classification for malignant tumors. This classification accounts the location and extension 
of the tumor, which might be organ confined or disseminated (lymph nodes, bones, liver 
and adrenal gland)12, 13. 
The letter T describes the size and degree of locoregional invasion of the primary 
tumor. The letter N indicates the extent of regional lymph node involvement and the letter 
M shows the presence of distant metastases (Figure 3)13.  
TNM can be based on clinical diagnostic examinations (cTNM) or based on 
surgical/pathological material (pTNM). Clinical classification is based on the evidence 
acquired before treatment, including physical examination, imaging studies, laboratory 
tests and staging procedures (bronchoscopy for example). Pathological classification uses 
the evidence acquired before treatment, supplemented or modified by the additional 
evidence acquired during and after surgery (particularly from pathologic examination). 
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TNM is essential to treatment planning, evaluation of treatment outcomes and prognosis 
determination14. 
The staging process is more efficient when several specific examinations are 
combined, as like blood tests, biopsies, surgical evaluation, CT scan or positron emission 
tomography (PET). Preoperative biopsies are less invasive and allows for an adequate 
sampling13. Furthermore, the recommended biopsy procedures for screen-detected 
suspicious pulmonary nodules resulted in a low intervention rate for benign nodules15. CT 
scan with contrast injection is the most requested staging technique since it allows 
visualization of metastasis in several organs. This exam has two major limitations namely 
the lack of ability to detect microscopic metastatic disease and the high rate of benign 
nodules’ detection. PET scan has a great sensitivity, allowing visualization of the 
metabolic activity of malignant disease. Moreover, it has the ability to characterize LCa 
nodular stage12, 13, 15.  
 
Figure 3 - Staging of lung cancer according to the TNM system13. 
1.1.5 Prognosis 
This disease is often asymptomatic in early stages. Thus, at diagnosis most of the 
patients present locally advanced or metastatic disease and therefore a worse prognosis. 
Patients with LCa have a cure rate of only 16%, even in the most advanced Western 
health systems. The prognosis of LCa is highly dependent on disease stage, being never-
smoking status and female sex favorable prognostic factors.9.  
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Nevertheless, the main criteria are performance status and disease extension at 
diagnosis (TNM stage), with the advanced stages displaying the worst prognosis7. 
 
1.1.6 Treatment 
LCa treatment depends on histopathological diagnosis, disease stage and 
patient’s general condition. There are several ways to treat LCa, including surgery, 
chemotherapy, radiation and targeted therapy (Figure 4)10. 
 
Figure 4 - Molecular diagnosis and treatment of lung cancer at different stages 10. 
1.1.6.1 Surgery 
Tumor resection by surgery remains the best and the most successful treatment 
approach for patients with early stage disease (stage I and II and selected patients with 
stage IIIA), whose LCa are limited to the hemithorax and can be totally encompassed by 
excision. Tumors can be removed by anatomic segmentectomy, pneumonectomy or 
lobectomy. Lobectomy is currently the standard care that will result in complete resection 
of the tumor mass. However the great majority of patients present at diagnosis time 
inoperable tumors12. 
1.1.6.2 Radiotherapy (RT) 
Radiotherapy (RT) is performed in patients with resectable tumors that are 
medically unfit or refuse to undergo surgical resection. In these cases RT is used to 
control primary tumor growth and regional lymphatic dissemination. Therapeutic doses of 
radiation must be delivered to the target site, minimizing incidental irradiation of 
surrounding normal tissues. This process typically requires a planning CT scan with the 
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patient in treatment position. The radiation oncologist defines the target and surrounding 
normal tissues on the CT images using special treatment planning software. RT is also 
used as adjuvant therapy for patients with incomplete resection or node-positive disease 
and as palliative therapy, controlling symptoms and improving life quality 12.   
1.1.6.3 Chemotherapy (ChT) 
Chemotherapy has become the standard care for treating SCLC and unselected 
advanced NSCLC, and has also been advocated as an integral part of combined modality 
approaches to disease earlier stages. Initially it was used in patients with advanced 
metastatic disease as a palliative measure. Currently is used with curative intent alone or 
combined with others therapies. It was demonstrated that induction chemotherapy 
followed by RT prolongs the overall survival of patients with unresectable stage III disease 
compared with patients receiving RT alone. Therefore, chemotherapy has an emerging 
role in stage IlIA (N2) disease. The use of induction chemotherapy in patients (stage IIIA) 
alone or in conjunction with RT, results in a 5-year survival of 20 to 30 % compared with 5 
to 10 % with surgery alone.9  
1.1.6.4  Targeted Therapy 
 The identification of new potential biomarkers led to a novel strategy, named 
targeted therapy. In the last years has been improved mainly due to the information from 
molecular studies that identify specific alterations in groups of LCa patients. Contrarily to 
other LCa treatments, which act directly against cancer cells or tumor, immunotherapy, is 
a more sophisticated method that stimulates the patient’s immune system to target cancer 
cells. This therapy in the majority of the cases presents less severe side effects. Several 
agents that target various molecular pathways are being studied (Figure 5)16, 17. 
Nowadays, the agents used for LCa treatment include: inhibitors and antibodies of 
epidermal growth factor receptor (EGFR); inhibitor of EML4-ALK inhibitors17. 
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Figure 5 - Proportion of known driver mutations in Non-small cell lung cancer(NSCLC)16. 
 EGFR 
Mutations in tyrosine kinases receptors, such as epidermal growth factor receptor 
(EGFR) are well known cancer predictive biomarker. When EGFR is constitutively 
activated by mutations there are several inhibitors that can be used namely: gefitinib, 
erlotinib, lapatinib and cetuximab. EGFR-targeted inhibitors include monoclonal 
antibodies, that target EGFR extracellular domain, and tyrosine kinase inhibitors (TKIs), 
which are small molecules that inhibit intracellular tyrosine kinase activity of EGFR. The 
somatic mutations at the kinase domain of EGFR strongly correlates with sensitivity to 
EGFR inhibitors, being observed in roughly 10-20% of cases of lung adenocarcinomas, 
from patients of European descent and in roughly 50% of cases from patients of East 
Asian descent. These proportions can be explained to local smoking rates (areas with 
high smoking rates have lower rates of EGFR- mutated cancers). These mutations 
preferentially affect patients with adenocarcinoma subtype who never smoked, females 
and East Asian ethnicity. EGFR mutation is not only a predictive biomarker to EGFR 
tyrosine kinase inhibitors but also a prognostic factor. Therefore, the presence and the 
type of EGFR mutations is indicative which of patients will respond to therapy with EGFR 
inhibitors (Figure 6)7, 8, 12, 16, 17. 
 EML4-ALK 
The inversion of two closely located genes on chromosome 2p, fusion of PTK 
echinoderm microtubule-associated protein like-4 (EML4) with anaplastic lymphoma 
kinase (ALK) yields the EML4-ALK fusion protein. The EML4 - ALK fused oncogene is 
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present in up to 3-7% of NSCLC and promotes malignant growth and proliferation. 
Similarly to EGFR alterations, ALK rearrangements are more likely to be seen in specific 
populations. Thus, young patients with adenocarcinoma subtype (mostly associated with  
an acinar pattern) who are light or never-smokers,  males and frequent signet ring cells 
seen on histology are the main subset of patients with ALK alterations and benefit from 
treatment with the ALK inhibitor crizotinib. Clinical testing guidelines for ALK fusion 
detection in lung adenocarcinoma is already standard care. Moreover, 
immunohistochemistry is also sensible and specific tool for ALK rearrangements detection 
(Figure 6)7, 8, 12, 16, 17. 
There are other potential biomarkers with therapeutic value, but without targeted 
therapies, yet (e.g. KRAS)16. 
 KRAS 
KRAS mutations are the most common oncogenic driver alteration at the tyrosine 
kinase receptor pathway of lung adenocarcinomas in Caucasian populations. In fact a 
mutation rate of roughly 30% has been described in these population compared to only 
10% in East Asian population. This mutation is associated with tobacco smoking which 
might explain this high percentage. KRAS mutation has been associated with poor 
prognosis, and importantly predicts chemotherapy and EGFR TKIs resistance. Although 
KRAS was one of the first described oncogenic drivers in NSCLC, effective targeting of 
this alteration remains a therapeutic challenge and no effective treatments for KRAS-
mutant lung adenocarcinomas have been discovered so far. Direct RAS inhibition with 
salirasib was been proved unsuccessful; hence novel approaches are currently tested to 
inhibit downstream molecules in the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR pathways 
(Figure 6)7, 8, 12, 16, 17. 
Targeted therapy for SCC is now a major focus of research. Recent discoveries 
from the cancer genome atlas (TCGA) about the molecular pathology of SCC have 
identified several important signaling pathways (Figure 5). Although these pathways can 
be inhibited, clinically meaningful benefits were not achieved yet. Ongoing work should 
hopefully see the identification of targeted agents for SCC in the near future16.  
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Figure 6 - Overview of molecular pathways and potential targets in Non-small cell lung cancer (NSCLC)16. 
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1.2 Epigenetics 
The term epigenetics derived from the Greek prefix epi- meaning “what stays 
beyond” –genetics. The original definition by Conrad Waddington (1941), epigenetics 
referred to all molecular pathways modulating the expression of a genotype into a 
particular phenotype. However, with the rapid growth of genetics, the meaning of the word 
has gradually narrowed. Epigenetics today is generally defined as ‘‘the study of heritable 
changes in gene function and that do not alter the primary DNA sequence’’.18  
1.2.1 Epigenetic Mechanisms 
Epigenetic mechanisms can be grouped into at least four major types of 
modifications: DNA methylation, non-coding RNAs, histone post-translational 
modifications and histone variants (Figure 7).19 These mechanisms are essential for 
normal development and maintenance of tissue-specific gene expression patterns in 
mammals. Abnormal epigenetic modifications were shown to contribute to common 
human diseases, including cancer 20. Indeed, deregulation of epigenetic mechanisms are 
present in all types of tumors, contributing to its development and progression.21 The 
reversible nature of epigenetic aberrations has led to the emergence of the promising field 
of epigenetic therapy.20 
 
Figure 7 - Four distinct mechanisms of epigenetic regulation 19. 
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1.2.1.1 Non-coding RNAs 
Non-coding RNAs (NcRNAs) are a class of RNA sequences that do not encode for 
proteins but are transcribed and biologically active. They are involved in a wide range of 
cellular functions, as chromosome dynamic control, splicing, RNA editing, translation 
inhibition and mRNA degradation. NcRNAs are composed by transcribed ultraconserved 
regions, small nucleolar RNAs, Piwi- interacting RNAs, large intergenic NcRNAs, long 
NcRNAs and microRNAs (miRNAs)22. MiRNAs are without doubt the best studied class. 
They are small non-coding RNA molecules that can negatively regulate the expression of 
up to hundreds of messenger RNA (mRNA) targets23. In normal cells, microRNAs are 
responsible for the fine-tuning of homeostatic gene expression and help to confer 
robustness to cellular processes, which is required for inducing and keeping cell fate 
decisions. MicroRNAs have also been implicated in the oncogenic transformation and 
their expression is altered at early stages of lung cancer10. 
1.2.1.2 Histone Post-translational Modifications and Variants 
In eukaryotic cells, chromatin is composed by DNA and histones, and it is in this 
context that transcription takes place. Histones are dynamic regulators of gene activity 
that undergo a wide variety of post-translational modifications influencing chromatin 
structure and recruitment of proteins complexes to DNA. Eight histones, one pair of each 
H2A, H2B, H3 and H4 constitute the basic unit of chromatin, the nucleosome. Histone H1 
binds to the DNA between the nucleosomes. Post-translational modifications of histones 
are an epigenetic mechanism for the establishment and maintenance of gene activity, and 
consequently, regulate a wide range of cellular processes. The best characterized post-
translational modifications are methylation, acetylation and phosphorylation24, 25 
1.2.1.3 DNA methylation 
DNA methylation is the best studied epigenetic modification being the major 
alteration that takes place during aging, embryogenesis and carcinogenesis26. 
The DNA methylation consists in the addition of methyl group (CH3) to the 5’carbon 
of a cytosine nucleotide preceding a guanine, originating 5-methylcytosine (5mC). This 
enzymatic addition is a normal process within cells25, 27. DNA methylation is catalyzed by a 
series of sophisticated enzymes called DNA methyltransferases (DNMTs) that use S-
adenosylmethionine (SAM) as a methyl donor group (Figure 8). Methylation in mammals 
primarily occurs in CpGs dinucleotides and only occasionally in non-CpG sites 17, 28, 29. 
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Figure 8 - Conversion of cytosine to 5-methylcytosine by DNA methyltransferase (DNMT). The methyl group 
(CH3) is transferred from S-adenosylmethionine (SAM) to 5-carbon position of cytosine by DNMT25. 
There are four known biologically active DNMTs in mammals: DNMT1, DNMT2, 
DNMT3a and DNMT3b.26 DNMIT1 is responsible for maintaining DNA methylation and 
copies pre-existing methylation pattern onto the newly synthetized strand immediately 
after DNA replication. DNMT1’ function is to ensure that the methylation pattern of the 
parental cells is identically reproduced in each daughter cell. There is considerable 
evidence indicating an upregulation of DNMT1 in cancer. DNMT2 just appears to be 
involved in methylation of RNA and has shown only weak DNA methylation ability in vitro. 
DNMT3a and DNMT3b are the enzymes responsible for de novo methylation at CpG sites 
during embryogenesis targeting unmethylated CpG dinucleotides. Even though DNMT1 
appear to be responsible for most of DNA-methylating capacity in cancer cells, specially at 
promoter regions, recent studies suggest an interaction between DNMT1 and DNMT3b to 
ensure propagation of methylation patterns during DNA replication in cancer cells21, 24-26 
In normal mammalian cells, CpG islands are proximal to gene promoter regions 
(Figure 9). These regions are largely protected from DNA methylation and reside in 
restricted regions of open chromatin, or euchromatic states, which are favorable to gene 
transcription. In contrast, for most regions of the genome, such as gene bodies, repeat 
elements and pericentromeric regions of the genome, cytosines in CpG dinucleotides are 
methylated (Figure 8). This pattern of DNA methylation is common to the bulk of the 
human genome, which is packed as closed unfavorable for transcription29.  
Global DNA hypomethylation occurs in cancer cells, which results in chromosomal 
instability and activation of proto-oncogenes. Concomitantly, abnormal methylation of 
gene promoter regions (hypermethylation) leads to tumor suppressor silencing (Figure 9). 
CpG islands, the major targets of DNA methyltransferases, are associated with the 
transcription start sites of almost half of human genes8. CG dinucleotides occur at a high 
frequency in tumor suppressor genes (TSG) promoters, and these CpG islands are 
usually unmethylated or hypomethylated in normal cells, allowing the initiation of 
transcription. However, during malignant transformation, CpG islands became methylated 
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or hypermethylated, leading to repression of TSG transcription and potentiating 
oncogenesis30. Despite CpG islands cover approximately 1% of the total human genome, 
they are present in >50% of human gene promoters which indicates their functional 
importance in transcriptional control24. Approximately 75% of all CpG dinucleotides in 
normal cells are methylated in the human genome21. 
 
Figure 9 - DNA methylation in normal and cancer cells. In normal cells, promoter Cpg islands are 
unmethylated while in cancer cells, they have acquired aberrant DNA methylation, and consequently, 
transcriptional silencing. Adapted from Baylin, 2015 29. 
The common occurrence of DNA hypermethylation in all types of cancer makes it 
an ideal biomarker, one that has been extensively investigated. DNA methylation is an 
inherently ideal substrate for cancer biomarker development for several key reasons. An 
advantage of DNA methylation over protein-based markers is that it is readily amplifiable 
and easily detectable using PCR-based approaches. Furthermore and, contrarily to 
cancer-specific DNA mutations, cancer-specific DNA hypermethylation occurs in defined 
regions, usually in or near the promoter of genes27. Moreover, the prevalence of CpG 
methylation changes at literally hundreds of genes in a given tumor affords a vast number 
of possible tumor-specific targets for assay development. Finally, its association with gene 
silencing allows DNA methylation to serve as a substitute marker for gene expression, 
effectively providing a positive reading for negative expression21. 
1.2.2 DNA methylation in Lung Cancer 
Lung cancer develops through a multistage process involving permanent genetic 
alterations, dynamic epigenetic changes and environmental factors (Figure 10)10.  
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Figure 10 - Cancer is a result of the interaction between permanent genetic mutations and dynamic epigenetic 
alterations. During cancer formation, a large number of epigenetic and genetic alterations lead to abnormal 
gene expression which evoke genome instability. Adapted from Mehta, 2015; Chen, 2014 10, 31. 
DNA methylation plays a critical role in repressing gene activity of several TSG 
and maintaining genome stability. It has been demonstrated that two major changes in 
methylation status occur during carcinogenesis: regional promoter hypermethylation and 
genome wide hypomethylation. These methylation changes are critically associated with 
transcriptional silencing of the involved genes26. 
It was suggested that LCa harbors a CpG island methylator phenotype, in other 
words a tumor phenotype characterized by widespread hypermethylation. This is not 
totally surprising, given the well-known upregulation of DNMTs in NSCLC23. 
DNA methylation plays an important role in the etiology of LCa, therefore it might 
have a potential value as diagnostic and prognostic biomarkers. Expanding our 
understanding of how epigenetic events contribute to the genesis of LCa and how they 
can be translated into clinical relevant biomarkers and therapeutic targets will enhance our 
capacity to manage LCa patients and consequently reduce the heavy global burden of this 
critical disease23. Research on epigenetic has provided new insights of early cancer 
development and progression, allowing increased knowledge of early stages of the 
disease and therapeutic interventions24.  
1.2.2.1 Hypermethylated genes in Lung Cancer 
Currently, there are many genes described as hypermethylated in LCa. Some of 
the most studied in this context and more informative include: APC, HOXA9, RARβ2, 
RASSF1A, SHOX2 and TFPI2 (Table 1) 32. 
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Table 1 - Panel of genes hypermethylated in lung cancer. 
Gene Locus Gene function References 
APC 5q22.2 
Adenomatous polyposis coli: TSG that 
acts as a negative regulator of Wnt and 
also is involved in cell migration and 
adhesion, transcriptional activation, and 
apoptosis 
33 
HOXA9 
7p15-7p14.2 
 
HOX genes encode transcription factors 
that play essential roles in regulation of 
embryonic morphogenesis in animals 
34 
RARΒ2 9p24.2 
Retinoic acid receptor beta is involved in 
cell growth and differentiation. 
5 
RASSF1A 3p21.31 
Ras association (RalGDS/AF-6) domain 
family member 1 is a putative TSG 
involved in apoptosis and cell cycle 
control 
35 
SHOX2 3q25.32 
Homeobox family gene is involved in gene 
transcription with putative involvement in 
cell growth and differentiation 
36, 37 
TFPI2 7q22 
TFPI2 decreases activation of 
metalloproteinases 
38, 39 
 
1.2.2.1.1 APC 
The adenomatous polyposis coli (APC) gene encodes for a cytoplasmic protein 
involved in cell signaling through Wnt pathway which plays an important role in cell-cycle 
regulation and apoptosis (Table 1)40, 41. The APC binds to β-catenin, axin and glycogen 
synthase kinase 3β to form a large protein complex, in which β-catenin is phosphorylated 
and broken down, resulting in negative regulation of the Wnt signaling pathway40. An 
impaired function of APC is often attributable to mutations within the coding sequence of 
the gene. This in turn leads to lack of degradation and nuclear accumulation of β-catenin 
which acts as a transcriptional activator, causing loss of cell growth control41. In addition, 
APC is involved in cell motility through its association with microtubules and it also 
stimulate guanine nucleotide exchange factor40. APC is considered a tumor suppressor 
gene and high APC promoter methylation is significantly associated with a decrease in 
survival at LCa. Therefore APC is promise a biomarker of biologically aggressive 
NSCLC42. 
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1.2.2.1.2 HOXA9 
HOX genes encode transcription factors that are critical in the regulation of 
embryonic morphogenesis in animals (Table 1)43. HOX proteins are essential switches of 
development stage-specific and cell-specific gene regulation. Thus, HOX proteins are key 
determinants of cell identity and potential targets during tumorigenesis44. Most of the 
HOXA promoters contain highly dense CpG islands, and its methylation is integral to the 
control of HOXA9 gene expression34. In LCa, HOXA9 displays higher methylation levels in 
tumor tissues than normal tissues. Therefore, detection of aberrant HOXA9 gene 
hypermethylation might be useful as biomarker for the early diagnosis of primary LCa45.  
1.2.2.1.3 RARβ2 
Retinoic acid is known to interact with nuclear retinoic acid receptors and retinoic X 
receptors. Both receptors have three subtypes (alpha, beta and gamma) which have 
distinct functions46. Receptors of the RAR family are differentially expressed during 
development and in adults life. There is strong evidence that RARβ plays a central role in 
epithelial cells growth regulation and in tumorigenesis47. The RARβ2 gene has two 
different promoters and transcripts which are produced by alternative splicing. Most 
human cells express RARβ2 as predominant form. This isoform plays a central role in 
mediation of growth inhibition of different types of cancer cells and is responsible for 
coding vitamin A nuclear receptor which is required for normal cell growth and 
differentiation (Table 1)48-50. RARβ2 expression is not only lost or reduced in a large 
percentage of LCa patients but also in a people with high risk to development LCa. 
Approximately 40% of NSCLC present loss or reduced RARβ246, 48.It was also described 
that RARβ2 hypermethylation might be associated with short recurrence-free survival in 
never-smokers adenocarcinoma’s patients 46. 
1.2.2.1.4 RASSF1A 
Ras association domain family 1 isoform A (RASSF1A) is a tumor suppressor 
gene whose inactivation is implicated in the development of many human cancers (Table 
1). It is termed RASSF1A because the protein contains a putative Ras association 
domain35. The RASSF1A protein, encoded by one of the 8 splicing isoforms, termed 1A to 
1H, is expressed in all normal human tissues, and carries several domains mediating 
protein-protein interactions with multiple partners51. RASSF1A modulates a broad range of 
essential cellular functions for normal growth control, such cell motility, invasion, cell cycle 
and apoptosis, regulation of microtubules and maintenance of genomic stability35. Besides 
this, it was also suggested that RASSF1A plays a role in tumor cell adhesion and 
motility51. This gene appears to suffer frequent transcriptional inactivation in tumor cells 
22 
 
due to aberrant promoter methylation35. It has been reported that RASSF1A gene is 
frequently inactivated in primary LCa by the de novo methylation of CpG islands in the 
promoter region52. Due to this, RASSF1A represents an important potential diagnostic 
target35. 
1.2.2.1.5 SHOX2 
The human Short Stature Homeobox 2 (SHOX2) has been identified as highly 
homologous to the short stature homeobox gene SHOX (Table 1). Homeobox genes code 
for proteins harboring specific DNA-binding homeodomains (homeoproteins), which play 
fundamental roles in vertebrate development and differentiation by acting as 
transcriptional regulators. SHOX2 is a known regulator of chondrocyte hypertrophy and 
act in skeleton development and embryogenic pattern formation36, 37. Genomic gain of 
chromosome 3q involving the SHOX2 gene has been recognized as one of the most 
prevalent and significant chromosomal rearrangements in LCa36. SHOX2 
hypermethylation was shown to be a useful biomarker for detecting SCC and SCLC with 
high specificity and sensitiviy36, 53. An in vitro diagnostic test for SHOX2 methylation has 
recently become commercially available in Europe, and it was demonstrated that it helped 
pathologists in the diagnosis of LCa with sensitivity of 68% and 95% of specificity54. 
1.2.2.1.6 TFPI2 
The human Tissue Factor Pathway Inhibitor 2 (TFPI2) is a potential inhibitor of the 
plasmin within the extracellular matrix. Degradation of this protein was strongly associated 
with the progression of LCa (Table 1)38. TFPI2 is synthesized and secreted by endothelial, 
mesenchymal and epithelial cells, monocytes/macrophages and the syncytiotrophoblast39. 
TFPI2 decreases activation of metalloproteinases (MMP1, MMP3, MMP9 and MMP13) 
which inhibit plasmin and trypsin leading to a reduction of tumor invasion and 
metastasis39, 55. Downregulation of TFPI2 promote migration and invasion of LCa lines. 
Thus TFPI2 is considered a TSG in LCa and aberrant TFPI2 promoter hypermethylation 
may be a valuable prognostic marker38. 
 
 
 
 
 
 
 
 
 
 
 
 
2. AIMS 
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Lung cancer, a complex disease involving both genetic and epigenetic changes, is 
the leading cause of cancer related deaths worldwide for both genders. The high mortality 
rate of this disease is mainly due to the high incidence coupled with its dismal 5-year 
survival rate of only 10%, despite the development of novel clinical diagnosis techniques 
and chemotherapy. The prognosis and treatment of LCa varies depending on subtype. 
Therefore, improved tools for early detection and discrimination of the different subtypes 
of LCa are urgently needed, in order to have a faster, efficient and targeted treatment, 
increasing in turn the survival rate of this disease. 
Several epigenetic alterations are involved in LCa development and progression. 
Since DNA methylation markers are stable and amenable to be easily assessed by PCR 
based measurement and due to their early onset, into LCa they might have potential in 
diagnosis and prognosis of this malignancy. Thus, the main objective of this master thesis 
was to evaluate the methylation profile of the different LCa subtypes, with a panel of 
previously described genes for LCa - APC, HOXA9, RARβ2, RASSF1A, TFPI2 and 
SHOX2. Particularly we aimed to discriminate adenocarcinoma, the most prevalent 
subtype, from the other major LCa subtypes. 
Thus, the specific aims of this master dissertation were: 
 Validate the previously identified DNA-methylation based markers (APC, HOXA9, 
RARβ2, RASSF1A, TFPI2 and SHOX2) in lung cancer tissue samples. 
 Identify a methylation profile of lung cancer major subtypes; 
 Evaluate the association between the gene-panel methylation levels and standard 
clinicopathological parameters 
 Determine the prognostic value of gene-panel methylation levels. 
 
 
 
 
 
 
 
 
 
 
 
 
3. MATERIALS AND METHODS 
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3.1 Study cohort – Patients and Samples 
For this study, 152 LCa samples, including 63 squamous cell carcinomas (SCC), 
58 adenocarcinomas (Ade), six large cell carcinomas (LCC) and 25 small cell carcinomas 
(SCLC), were obtained from the archives of the Department of Pathology. All the tumor 
tissue samples were obtained from tumorectomy specimens of patients diagnosed and 
treated at the Portuguese Oncology Institute of Porto with no previous history of lung 
cancer. Tissues were routinely fixed and paraffin-embedded for standard pathologic 
examination, allowing for tumor classification and World Health Organization7/AJCC 
Cancer Staging Manual14 grading and staging. Additionally, an independent set of 22 
paraffin-embedded normal pulmonary parenchyma collected from individuals with other 
neoplasias was used as controls. Relevant clinical data were collected from clinical charts. 
This study was approved by institutional ethics review board (CES-IPOPFG-EPE 
120/015). 
3.2  DNA Extraction From Formalin-fixed Paraffin-
embedded Tissues (FFPE) 
For each case, the slides, that were previously stained with Hematoxylin & Eosin 
were delimited the area with tumor cells. Tumor areas were macrodissected from the 
eight-micrometer thick tissue sections to maximize the proportion of malignant cells 
(>70%), and subsequently deparaffinized and rehydrated using xylene and 100% ethanol. 
Then samples were digested with proteinase K (20 mg/ml, 60μl). DNA was extracted 
using standard phenol-chloroform, ethanol, ammonium chloride and glycogen protocol. 
After elution, DNA concentration was measured by NanoDrop Lite Spectrophotometer 
(NanoDrop Technologies, USA) and stored at -20°C (Appendix I). 
3.3  Bisulfite treatment of DNA, quantitative methylation- 
specific polymerase chain reaction (qMSP) 
Bisulfite treatment of DNA samples was performed using EZ DNA methylation – 
Gold kit (Zymo Research, Orange, CA), and the converted DNA was eluted in 36-60μl of 
distilled water and stored at -80ºC (Appendix II). This method allows for the assessment of 
the methylation status of individual CpG islands in genomic DNA. The major advantage of 
sodium bisulfite-based assays is that they require very small amounts of DNA and 
consequently, are compatible with DNA obtained from macrodissected paraffin-embedded 
tissue samples56. 
27 
 
 
Figure 11 – DNA modification by sodium bisulfite. Following bisulfite conversion, methylated cytosines remain 
unchanged, while unmethylated cytosines are deaminated to uracils. The level of DNA promoter 
hypermethylation its quantified by quantitative methylation-specific PCR (qMSP). 
Quantitative methylation-specific PCR (qMSP) was performed using the bisulfite-
modified DNA as the template. Reactions were carried out in 384-well plates using 
LightCycler 480 (Roche, Germany). Briefly, per each well 2 μL of modified DNA and 5 μL 
of KAPA SYBR® FAST qPCR Master. The volume of primers used varied (according to 
Table 2) and sterile distilled water was added in order to total 10 μL of reaction volume 
(Appendix III). The thermocycler conditions were as follows: initial denaturation at 95ºC for 
3min; followed by 40 cycles of 95ºC for 3s, 30s for annealing, extension and data 
acquisition (temperature specified in Table 2).  
The β-Actin (ACTβ) gene was used for normalization and control of the quantity of 
DNA. The relative level of methylated DNA for each gene in each sample was determined 
by the comparison between values obtained for each target gene and values of the 
internal reference gene. The ratio was then multiplied by 1000 for easier tabulation ([ML = 
(target gene/ACTβ) x 1000]). Experiments were performed in triplicate, with water blanks 
as negative controls and five serial dilutions (dilution factor of 5) of a fully methylated 
bisulfite modified universal DNA control (in vitro methylated human DNA, Chemicon). PCR 
primers are described in Table 2. 
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Table 2 - Primers sequences used and qMSP conditions for each of the tested genes. 
Gene Forward (F) Reverse (R) 
Annealing 
TºC 
Concentration 
per reaction (F 
+ R) 
β-Actin 
 
TGGTGATGG
AGGAGGTTT
AGTAAGT 
 
AACCAATAAA
ACCTACTCC
TCCCTTAA 
60 400 nM 
APC 
 
TGTGTTTTAT
TGCGGAGTG
C 
CACATATCG
ATCACGTAC
GC 
62 300 nM 
HOXA9 
 
TATTTAGTCG
GTATTCGC 
ACCTCGAAC
GCTTCCAT 
60 300 nM 
RARβ2 
 
TCGAGAACG
CGAGCGATT 
GACCAATCC
AACCGAAAC 
60 300 nM 
RASSF1A 
 
GGGTTTTGC
GAGAGCGCG 
 
GCTAACAAA
CGCGAACCG 
60 300 nM 
SHOX2 
 
ATTCGTATTT
GGTCGCGTA
C 
CTACTACGA
CCGCCACTA
CC 
62 300 nM 
TFPI2 
 
GGCGGGGT
GATAGTTTTC 
 
TACTCCAAA
CGACCCGAA
T 
62 300 nM 
 
3.4  Statistical analysis 
Differences in methylation levels of tested genes among the histological subtypes 
were assessed by the non-parametric Kruskall-Wallis test, followed by pairwise 
comparisons through Mann-Whitney U Test.  
The Kaplan-Meier method was employed to estimate the probability of survival as a 
function of time and survival differences were analyzed by the log-rank test. 
A Cox-regression model comprising clinicopathological variables was computed to 
assess the relative contribution of each variable to the follow-up status. 
Two-tailed P-values were derived from statistical tests, using a computer assisted 
program (SPSS Version 22.0, Chicago, IL), and results were considered statistically 
significant at P < 0.05, with Bonferroni´s correction for multiple tests, when applicable.
  
 
 
 
 
 
 
 
 
 
4. RESULTS 
 
 
 
 
 
30 
 
4.1 Clinical Samples 
A total of 250 patients were initially enrolled in this study. However, because most 
lung cancers are not surgically treated, especially LCC, tissue availability is restricted to 
small biopsies from which good quality DNA is difficult to obtain, due to these limitations, 
only 152 tumors were selected for testing. These patients were consecutively diagnosed 
from 2001 to 2015,. Of these patients, 113 (74.3%) were male and 39 (25.6%) were 
females, with a median age of 64 years (range, 45 – 83) (Table 3). 
 
Table 3 - Clinical and Histopathological characteristics of patients with Lung cancer and Normal pulmonary 
parenchyma. 
 
CLINICOPATHOLOGIC 
CHARACTERISTICS 
 
 
LUNG CANCER PATIENTS 
(LCa) 
 
NORMAL LUNG (NL) 
Patients, n 
 
 
152 22 
Gender, n 
 
Male 
 
Female 
 
 
113 
 
39 
 
18 
 
4 
Age median, years (range) 
 
 
 
64 
 
(45 – 83) 
 
47 
 
( 2 – 75) 
Histological Subtype, n / (%) 
 
Adenocarcinoma 
 
Squamous Cell Carcinoma 
 
Large Cell Carcinoma 
 
Small Cell Lung Cancer 
 
 
58 (28 Male; 30 Female) / 39% 
 
63 (60 Male; 3 Female) / 41% 
 
6 (6 Male) / 4% 
 
25 (19 Male; 6 Female) / 16% 
 
n.a. 
 
n.a. 
 
n.a. 
 
n.a. 
Pathological stage, n 
 
Stage I 
 
Stage II 
 
Stage III 
 
Stage IV 
 
74 
 
33 
 
24 
 
21 
 
n.a. 
 
n.a. 
 
n.a. 
 
n.a. 
Differentiation 
 
Well 
 
Moderate 
 
Poor 
 
Not available 
 
 
 
22 
 
74 
 
25 
 
31 
 
 
 
n.a. 
 
n.a. 
 
n.a. 
 
22 
 
      n.a. Not applicable 
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Clinical characteristics of all patients enrolled in this study are summarized in 
Table 3. The majority of patients did not acknowledge smoking habits and, thus, we 
excluded this variable from analysis. 
 
4.2  Assessment of aberrant promoter methylation levels 
in LCa and controls 
  RASSF1A methylation levels were significantly higher in LCa compared to controls 
(P < 0.001), whereas for APC, RARβ2 and HOXA9 significantly higher methylation levels 
were found in controls (P < 0.001; P < 0.001; P < 0.001; respectively). However ROC 
curve analysis was not performed because in controls no RASSF1A promoter methylation 
was found (Figure 12). 
 
Figure 12 - Boxplots of (A) APC, (B) HOXA9, (C) RARβ2 and (D) RASSF1A promoter methylation levels 
between Lung Cancer (LCa) and normal lung (NL) samples. 
Moreover, no statistically significant differences were depicted for SHOX2 and 
TFPI2 promoter methylation between LCa and control samples (Appendix III). 
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4.3  Association between quantitative promoter 
methylation and clinicopathological parameters 
No significant associations were found between promoter methylation levels and 
patients’ age, gender or tumor differentiation. However, a significant association was 
found between methylation levels of APC, RARβ2 and RASSF1A and advanced 
pathological stage [APC (P < 0.001), RARβ2 (P < 0.001) and RASSF1A (P= < 0.001), 
(Figure 13)].  
 
Figure 13 - Boxplots of the methylation levels of (A) APC, (B) RARβ2 and (C) RASSF1A in the different 
stages (Mann Whitney Test, **P < 0.010; P*** < 0.01 ).  
 
4.4 Distribution of methylation levels according to major 
LCa subtypes  
Overall, APC, HOXA9, RARβ2 and RASSF1A methylation levels were significantly 
different between the two major LCa subtypes (NSCLC and SCLC) (***P < 0.001; *P = 
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0.021; ***P < 0.001; ***P < 0.001; respectively) (Appendix IV). Specifically, methylation 
levels of the four genes were higher in SCLC than in NSCLC (Figure 14). 
 
Figure 14 – Boxplots of (A) APC, (B) HOXA9, (C) RARβ2 and (D) RASSF1A promoter methylation levels 
between the major subtypes of Lung Cancer (LCa) samples. (NSCLC: Non-small cell lung cancer) (Mann 
Whitney Test, *P < 0.001; P*** < 0.01) 
4.5  Distribution of methylation levels according to LCa 
histological subtypes 
Methylation levels of all genes, except for SHOX2 and TFPI2 differed significantly 
among the four LCa subtypes (p < 0.001 for all, Kruskal-Wallis test). Pair-wise 
comparisons are shown in Table 4 and graphically illustrated in Figure 15 (Appendix V). 
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Table 4 - Kruskal Wallis and Mann Whitney tests analyze of APC, HOXA9, RARβ2, RASSF1A, SHOX2 and 
TFPI2 promoter methylation levels between subtypes of Lung Cancer (LCa) samples. 
 APC HOXA9 RARβ2 RASSF1A SHOX2 TFPI2 
Ade vs SCLC 0.000 0.006 0.000 0.000 0.714 0.104 
SCC vs SCLC 0.000 0.096 0.000 0.000 0.694 0.112 
LCC vs SCLC 0.069 0.441 0.009 0.095 0.976 0.555 
Ade vs SCC 0.632 0.000 0.697 0.259 0.409 0.993 
Ade vs LCC 0.634 0.140 0.133 0.226 0.880 0.991 
SCC vs LCC 0.593 0.976 0.174 0.097 0.485 0.976 
P  value 1 0.000 0.000 0.000 0.000 0.828 0.423 
1Kruskal Wallis test; Ade – Adenocarcinoma; SCLC – Small Cell Lung Cancer; SCC – Squamous Cell 
Carcinoma; LCC- Large Cell Carcinoma 
 
Generally, SCLC showed the highest methylation levels, significantly differing from 
Ade for the four genes (APC, HOXA9, RARβ2 and RASSF1A) and from SCC in three 
genes (APC, RARβ2 and RASSF1A), whereas only differed from LCC for RARβ2 
methylation (Table 5 and Figure 15). Interestingly, Adenocarcinomas and SCC only 
differed for HOXA9 methylation levels.  
Table 5 - Distribution of promoter methylation levels of cancer-related genes in Lung Cancer (LCa) samples 
measured by qMSP. 
 NSCLC Median (IQR) 
SCLC Median 
(IQR) 
 SCC Ade LCC 
APC 
5.758                  
(0.954-16.563) 
6.079                 
(1.379-14.482) 
10.784                 
(0.705-80.732) 
53.867                 
(19.824-211.923) 
HOXA9 
17.902                  
(10.476-78.753) 
7.348                 
(2.666-22.343) 
23.704                 
(7.570-174.509) 
77.104                 
(11.193-300.859) 
RARβ2 
4.233                  
(0.941-13.982) 
3.002                
(0.818-15.012) 
9.941                 
(4.445-37.177) 
113.573                 
(28.928-314.484) 
RASSF1A 
2.230                  
(0.191-15.362) 
3.269                 
(0.757-19.102) 
6.240                 
(3.549-445.682) 
438.113                
(20.601-2037-
204) 
SHOX2 
11.226                  
(1.942-36.750) 
6.198                 
(1.014-43.109) 
6.736                 
(1.581-29.858) 
13.377                
(0.000-675.465) 
TFPI2 
0.000                  
(0.000-2.429) 
0.000                 
(0.000-1.163) 
0.000                
(0.000-538.651) 
0.000                
(0.000-0.000) 
Ade – Adenocarcinoma; SCLC – Small Cell Lung Cancer; SCC – Squamous Cell Carcinoma; LCC- Large 
Cell Carcinoma; IQR- Interquartile range 
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Figure 15 – Boxplots of (A) APC, (B) HOXA9, (C) RARβ2 and (D) RASSF1A promoter methylation levels 
between subtypes of Lung Cancer (LCa) samples. (SCC: Squamous cell carcinoma; Ade: Adenocarcinoma; 
LCC: Large cell carcinoma; SCLC: Small cell lung cancer) (Mann Whitney Test, *P < 0.001; P*** < 0.01) 
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Therefore, the analyzed genes are able to discriminate among different LCa 
subtypes (Figure 16). 
 
Figure 16 – Schematic representation of the association between genes promoter methylation and 
discrimination of major and minor Lung Cancer (LCa) subtypes. (NSCLC: Non-small cell lung cancer; SCLC: 
small cell lung cancer) 
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4.6  Survival analyses 
The median follow-up of this LCa patient cohort was 41 months (range: 1-174 
months). At the time of last follow-up, 80 patients were alive with no evidence of cancer, 8 
patients were alive with cancer progression and 64 patients had deceased, 52 of which 
due to LCa.  
4.6.1 Disease- Specific Survival 
For statistical purposes, RASSF1A, RARβ2, APC and HOXA9 methylation levels 
were dichotomized using the percentile 75, whereas for SHOX2 and TFPI2 the percentile 
50 was used as threshold value. DSS analysis showed that patients with higher 
RASSF1A, RARβ2, APC and HOXA9 promoter methylation levels had a significantly 
shorter survival (P < 0.001; P < 0.001; P < 0.001; P = 0.001; respectively; Figure 17; 
Table 6). This was not observed for SHOX2 and TFPI2 promoter methylation, thus we 
only further analyzed RASSF1A, RARβ2, APC and HOXA9 methylation. 
 
Figure 17 - Disease-Specific Survival according to (A) APC, (B) HOXA9, (C) RARβ2 and (D) RASSF1A 
methylation levels. 
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Concerning clinicopathological variables, poor differentiation, higher pathological 
stage and LCC and SCLC subtypes were significantly associated with worse prognosis 
(Figure 18 and Table 6). Thus we only further analyzed the significant variables. 
 
 
Figure 18 – Disease-Specific Survival according to (A) Differentiation grade, (B) Stage and (C) Histological 
subtypes. (SCC: Squamous cell carcinoma; Ade: Adenocarcinoma; LCC: Large cell carcinoma; SCLC: Small 
cell lung cancer) 
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Table 6 – Univariate Cox regression analyses assessing the potential of clinical and epigenetic variables in 
the prediction of disease-specific survival for 152 LCa patients. 
DISEASE-SPECIFIC 
SURVIVAL 
VARIABLES 
HAZARD RATIO 
(HR) 
95 % CI for OR P value 
 
UNIVARIABLE 
 
Age diagnosis 
 
1.02 (0.99 – 1.06) 0.177 
 
Gender 
 
2.20 (0.99 – 4.91) 0.054 
 
Differentiation 
 
          Well vs Moderate 
          Well vs Poor 
 
 
 
          2.06 
          9.28 
 
 
 
(0.45 - 9.43) 
(2.10 – 41.00) 
 
 
 
0.350 
0.003 
 
Stage 
 
          I vs II & III 
          I vs IV 
 
 
 
          2.33 
         18.57 
 
 
 
(1.14 – 4.79) 
(8.57 – 40.25) 
 
 
 
0.021 
0.000 
 
Histological Subtype 
 
          Ade vs SCC 
          Ade vs LCC 
          Ade vs SCLC 
 
 
 
2.08 
4.89 
17.85 
 
 
 
(0.90 – 4.81) 
(1.03 – 23.29) 
(7.60 – 41.95) 
 
 
 
0.085 
0.046 
0.000 
APC 
methylation ≥ p75 
3.71 (2.08 – 6.60) 0.000 
HOXA9 
methylation ≥ p75 
2.57 (1.44 – 4.58) 0.001 
RARβ2 
methylation ≥ p75 
2.77 (1.55 – 4.91) 0.000 
RASSF1A 
methylation ≥ p75 
2.96 (1.66 – 5.26) 0.000 
SHOX2 
methylation ≥ p50 
1.41 (0.79 – 2.52) 0.246 
 
TFPI2 
methylation ≥ p50 
0.75 (0.42 – 1.36) 0.344 
Ade: Adenocarcinoma; SCC: Squamous Cell Carcinoma; LCC: Large Cell Carcinoma; SCLC: Small Cell Lung Cancer 
 
To identify which independent factors jointly had a significant influence on overall 
survival, the Cox proportional hazards modeling technique was applied. Hence, we 
introduced in a Cox-regression model for DSS all statistically significant variables (stage, 
histological subtypes, differentiation, APC, HOXA9, RARβ2 and RASSF1A), that were 
selected in the final model as independent predictors of outcome. The degrees of 
differentiation are not applicable to SCLC and LCC, thus, these subtypes were excluded 
from analysis by Cox regression model. 
The multivariate models for APC, HOXA9, RARβ2 and RASSF1A demonstrated 
that shorter DSS was dependent of poor differentiation (Table 7, 8, 9 and 10). Patients 
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with poorly differentiated tumors and high RASSF1A, RARβ2, APC and HOXA9 promoter 
methylation levels had an 8.19-fold, 10.34-fold, 8.98-fold and 8.10-fold increased 
likelihood of dying from LCa, respectively. Therefore, none of the molecular variables 
retained independent prognostic value in multivariable analysis. 
Table 7 - Multivariate Cox regression analyses assessing the potential of clinical and epigenetic variables in 
the prediction of disease-specific survival for 152 LCa patients. 
DISEASE-SPECIFIC 
SURVIVAL 
VARIABLES 
HAZARD RATIO 
(HR) 
95 % CI for OR P value 
 
MULTIVARIABLE 
 
Differentiation 
 
          Well vs Moderate 
          Well vs Poor 
 
 
 
          1.84 
          8.10 
 
 
 
(0.36 – 9.26) 
(1.53 – 42.81) 
 
 
 
0.462 
0.014 
 
Stage 
 
          I vs II & III 
          I vs IV 
 
 
 
          1.60 
          0.00 
 
 
 
(0.72 – 3.54) 
(0.00 – 0.00) 
 
 
 
0.249 
0.981 
 
Histological Subtype 
 
          Ade vs SCC 
 
 
1.02 
 
 
(0.39 – 2.66) 
 
 
0.976 
 
APC 
methylation ≥ p75 
 
1.09 (0.44 – 2.73) 0.853 
Ade: Adenocarcinoma; SCC: Squamous Cell Carcinoma 
 
Table 8 - Multivariate Cox regression analyses assessing the potential of clinical and epigenetic variables in 
the prediction of disease-specific survival for 152 LCa patients.  
DISEASE-SPECIFIC 
SURVIVAL 
VARIABLES 
HAZARD RATIO 
(HR) 
95 % CI for OR P value 
 
MULTIVARIABLE 
 
Differentiation 
 
          Well vs Moderate 
          Well vs Poor 
 
 
 
          1.79 
          8.98 
 
 
 
(0.36 – 9.10) 
(1.73 – 46.70) 
 
 
 
0.478 
0.009 
 
Stage 
 
          I vs II & III 
          I vs IV 
 
 
 
          1.89 
          0.00 
 
 
 
(0.82 – 4.39) 
(0.00 – 0.00) 
 
 
 
0.136 
0.981 
 
Histological Subtype 
 
          Ade vs SCC 
 
 
 
1.12 
 
 
 
(0.43 – 2.92) 
 
 
 
0.819 
 
HOXA9 
methylation ≥ p75 
 
0.601 (0.22 – 1.63) 0.316 
Ade: Adenocarcinoma; SCC: Squamous Cell Carcinoma 
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Table 9 - Multivariate Cox regression analyses assessing the potential of clinical and epigenetic variables in 
the prediction of disease-specific survival for 152 LCa patients.  
DISEASE-SPECIFIC 
SURVIVAL 
VARIABLES 
HAZARD RATIO 
(HR) 
95 % CI for OR P value 
 
MULTIVARIABLE 
 
Differentiation 
 
          Well vs Moderate 
          Well vs Poor 
 
 
 
          1.93 
         10.34 
 
 
 
(0.39 – 9.89) 
(1.92 – 54.71) 
 
 
 
0.419 
0.007 
 
Stage 
 
          I vs II & III 
          I vs IV 
 
 
 
          1.92 
          0.00 
 
 
 
(0.85 – 4.24) 
(0.00 – 0.00) 
 
 
 
0.116 
0.981 
 
Histological Subtype 
 
          Ade vs SCC 
 
 
 
1.02 
 
 
 
(0.39 – 2.65) 
 
 
 
0.969 
RARβ2 
methylation ≥ p75 
0.48 (1.64 – 1.38) 0.173 
Ade: Adenocarcinoma; SCC: Squamous Cell Carcinoma 
 
Table 10 - Multivariate Cox regression analyses assessing the potential of clinical and epigenetic variables in 
the prediction of disease-specific survival for 152 LCa patients.  
DISEASE-SPECIFIC 
SURVIVAL 
VARIABLES 
HAZARD RATIO 
(HR) 
95 % CI for OR P value 
 
MULTIVARIABLE 
 
Differentiation 
 
          Well vs Moderate 
          Well vs Poor 
 
 
 
          1.84 
          8.19 
 
 
 
(0.37 – 9.25) 
(1.56 – 42.96) 
 
 
 
0.461 
0.013 
 
Stage 
 
          I vs II & III 
          I vs IV 
 
 
 
          1.58 
          0.00 
 
 
 
(0.72 – 3.49) 
(0.00 – 0.00) 
 
 
 
0.256 
0.987 
 
Histological Subtype 
 
          Ade vs SCC 
 
 
2.08 
 
 
(0.39 – 2.64) 
 
 
0.981 
 
RASSF1A 
methylation ≥ p75 
 
1.21 (0.48 – 3.05) 0.687 
Ade: Adenocarcinoma; SCC: Squamous Cell Carcinoma 
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4.6.2 Disease-Free Survival 
Recurrence is an important endpoint in LCa, thus we tested the prognostic value of 
clinicopathological variables and gene promoter methylation levels in this setting. 
For statistical purposes, RASSF1A and TFPI2 methylation levels were 
dichotomized using percentile 75, HOXA9 and SHOX2 using percentile 50, and RARβ2 as 
well as APC using percentile 25, as threshold values.  
Only differentiation grade and RASSF1A methylation levels were statistically associated 
with shorter DFS in univariate analysis (P = 0.005; P = 0.034; respectively) (Figure 19; 
Table 11). Thus, we only analyzed the association between these variables and DFS in 
multivariable model.  
 
Figure 19 - Disease-Free Survival according to (A) Differentiation grade, (B) RASSF1A methylation level. 
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Table 11 – Univariate Cox regression analyses assessing the potential of clinical and epigenetic variables in 
the prediction of disease-free survival for 152 LCa patients. 
DISEASE-FREE 
SURVIVAL 
VARIABLES 
HAZARD RATIO 
(HR) 
95 % CI for OR P value 
 
UNIVARIABLE 
 
Age diagnosis 
 
0.972 (0.93 – 1.01) 0.164 
 
Gender 
 
0.521 (0.22 – 1.26) 0.147 
 
Differentiation 
 
          Well vs Moderate 
          Well vs Poor 
 
 
 
          2.71 
          5.71 
 
 
 
(0.80 - 9.24) 
(1.60 – 20.49) 
 
 
 
0.110 
0.008 
 
Stage 
 
          I vs II & III 
          I vs IV 
 
 
 
          1.83 
          0.00 
 
 
 
(0.93 – 3.60) 
(0.00 – 0.00) 
 
 
 
0.08 
0.98 
 
Histological Subtype 
 
 
          Ade vs SCC 
          Ade vs LCC 
          Ade vs SCLC 
 
 
 
1.64 
0.98 
2.28 
 
 
 
(0.80 – 3.36) 
(0.13 – 7.56) 
(0.296 – 17.58) 
 
 
 
0.176 
0.985 
0.428 
APC 
methylation ≥ p25 
1.61 (0.819 – 3.17) 0.167 
HOXA9 
methylation ≥ p50 
1.66 (0.69 – 4.01) 0.260 
RARβ2 
methylation ≥ p25 
2.18 (0.90 – 5.28) 0.083 
 
RASSF1A 
methylation ≥ p75 
 
2.18 (1.04 – 4.57) 0.039 
SHOX2 
methylation ≥ p50 
1.15 (0.59 – 2.26) 0.679 
 
TFPI2 
methylation ≥ p75 
0.65 (0.27 – 1.57) 0.332 
Ade: Adenocarcinoma; SCC: Squamous Cell Carcinoma; LCC: Large Cell Carcinoma; SCLC: Small Cell Lung Cancer 
 
Similar to DSS, patients with poorly differentiated tumors and concomitant high 
RASSF1A promoter methylation levels had shorter DFS and a 5.39-fold increased hazard 
ratio (Table 12). Thus, high RASSF1A methylation levels does not independently predict 
for shorter DFS. 
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Table 12 - Multivariate Cox regression analyses assessing the potential of clinical and epigenetic variables in 
the prediction of disease-free survival for 152 LCa patients 
DISEASE-FREE 
SURVIVAL 
VARIABLES 
HAZARD RATIO 
(HR) 
95 % CI for OR P value 
 
MULTIVARIABLE 
 
Differentiation 
 
          Well vs Moderate 
          Well vs Poor 
 
 
 
2.59 
5.39 
 
 
 
(0.76 – 8.81) 
(1.50 – 19.42) 
 
 
 
0.129 
0.010 
 
RASSF1A 
methylation ≥ p75 
 
2.08 (0.96 – 4.51) 0.064 
 
 
 
 
 
 
 
 
 
 
 
5. DISCUSSION 
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Lung cancer is the most common malignancy in both genders and the most frequent 
cause of cancer-related death. Currently, no screening test is available for LCa, thus, 
patients suspected of having LCa are diagnosed because of symptoms, routine exams or 
secondarily to other clinical imaging investigations. The importance of an early diagnosis 
along with personalized therapy is currently acknowledged as major issues in LCa 
management57. Thus, accurate LCa subtype discrimination is critical to reduce mortality 
rate through improvement of therapeutic strategies. 
Using aberrantly methylated genes, we attempted to discriminate LCa from normal 
tissues. RASSF1A methylated levels discriminated LCa from controls. Nevertheless, the 
normal tissues used showed higher APC, RARβ2 and HOXA9 methylation levels 
comparing to LCa. This might be related with the origin of the control tissues. These were 
procured from patients with lung metastasis from non-pulmonary neoplasms, to avoid a 
possible “field-effect phenomenon” in lung tissues from lung cancer patients. Because the 
tumors involving the lung in those cases were metastatic, it was assumed that pulmonary 
parenchyma was normal. Thus, finding high promoter methylation levels for some genes 
might either represent an effect of aging, alterations due to previous therapy or 
contamination with tumor cells at distance. Concerning SHOX2 and TFPI2 aberrant 
methylation, no significant differences were disclosed between LCa and NL samples, 
contrarily to other reports on SHOX2 promoter methylation in lung cancer 61, 37, 54 . 
Consequently we focused mostly in LCa subtypes’ discrimination.  
Interestingly, APC, RARβ2 and RASSF1A promoter methylation levels significantly 
associated with advanced pathological stage. Nevertheless, Kim et al.52 and Endoh et al.62 
did not find significant associations between RASSF1A promoter methylation levels and 
pathological stage and Usadel et al41 also showed no association between APC 
methylation levels and LCa stage. Contrarily, Ponomaryova et al.49 reported that 
increased RARβ2 methylation levels in cell-free DNA were associated with tumor stage. 
These discrepancies might be explained by the subtype of the analyzed tumors and the 
clinical samples, as well as differences in the methylation assessment methodologies. It 
should be recalled that most of the cases in this series derive from surgical specimens, 
thus representing mostly LCa that are clinically amenable to curative-intent excision, 
which correspond to early stage tumors. 
Concerning the major LCa subtypes (NSCLC and SCLC), our results indicate that APC, 
RASSF1A, RARβ2 and HOXA9 methylation levels can discriminate these subtypes, 
however the same was not observed for SHOX2 and TFPI2 methylation levels. 
Furthermore higher APC, RASSF1A, RARβ2 and HOXA9 methylation levels were found in 
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SCLC compared to NSCLC. Our findings contradict those of Virmani et al 33, which found 
higher APC methylation levels in NSCLC cell lines. This might be due to the different 
methodological approach, since we have used quantitative whereas they have used 
qualitative methylation-specific PCR. Indeed, quantitative MSP is a sensitive and specific 
methodology that requires only minute amounts of DNA. It is able to differentiate between 
methylated and unmethylated DNA and consequently quantify the methylation level of 
sample using oligonucleotides whose 3’-ends match the methylation status of specific 
CpG sites in a bisulfite-treated template 63 64. However, MSP it is not quantitative, and 
may, thus, lead to false positive results when the PCR conditions used are not optimal. 
Moreover specificity of MSP is significantly lower compared to that of qMSP63, 65, 66.  
Conversely, the distribution of both RASSF1A and RARβ2 methylation levels were 
similar to those of previous reports 47, 62, 67-69. Regarding SHOX2 and TFPI2 the same was 
not observed. Both genes were found to be highly methylated in SCLC 37, 38, 54, 55, in 
contrast our results whereas TFPI2 showed basal methylation levels in both subtypes. 
Concerning HOXA9, high HOXA9 methylation levels were described in NSCLC 34, 45, 70, 
however at our knowledge no data were published so far concerning SCLC, probably due 
to scarcity of specimens available compared with NSCLC, a much more frequent 
malignancy despite being less aggressive 55.  
The originality of this dissertation lies in the assessment of methylation levels of 
cancer-related genes to discriminate LCa subtypes. Therefore we observed that APC, 
HOXA9, RARβ2 and RASSF1A might discriminate among some minor subtypes, but the 
same was not observed for SHOX2 and TFPI2. 
APC, HOXA9, RARβ2, and RASSF1A promoter methylation levels were able to 
distinguish adenocarcinomas from SCLC. Nonetheless, Guo et al.71 reported that APC 
methylation status strongly associated with NSCLC, especially with adenocarcinoma, but 
did not discriminate this subtype from others. Our results also showed that APC, RARβ2 
and RASSF1A methylation levels discriminate SCC from SCLC. Moreover, we 
demonstrated that RARβ2 methylation levels are able to discriminate LCC from SCLC, 
whereas HOXA9 distinguished adenocarcinoma from SCC in agreement with results 
reported by Hwang et al.45. However, contrarily to Kneip et al.54 no significant differences 
were reported among minor subtypes relatively to SHOX2 promoter methylation levels. 
Different assay sensitivity and small sample size might be the reasons for these 
discrepancies. Virmani et al.47 found that frequencies in RARβ2 gene promoter 
methylation did not differ significantly between adenocarcinomas (37%) and SCC (54%), 
which further confirms our observations. On other hand, Ponomaryova et al.49 described 
that in SCC patients, RARβ2 methylation levels in the cell surface blood of cell free DNA 
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was higher compared with patients with adenocarcinoma. There are a number of possible 
reasons for this divergence, including specific physiological characteristics in the 
progression of each tumor or the quantity and quality of DNA template extracted from 
FFPE tissues and other factors. 
The last goal of this dissertation consisted on the determination of the prognostic value 
of candidate methylated genes.  
In univariate analysis, most standard clinicopathological parameters associated with 
DSS (differentiation grade, stage, subtype) or DFS (tumor differentiation). Moreover, 
higher APC, RASSF1A, RARβ2 and HOXA9 methylation levels associated with shorter 
DSS, whereas higher RASSF1A methylation levels also associated with shorter DFS. To 
verify these correlations, multivariate regression models were established.  
However, in multivariate analysis only tumor differentiation retained independent 
prognostic value, both for DSS and DFS. Several studies verified a significant association 
between genes’ promoter hypermethylation and poorly differentiated LCa72-74, which is in 
line with our results. However, contrarily to other studies no associations were found 
between APC, TFPI2, HOXA9 and RARβ2 methylation levels and poor prognosis34, 38, 41, 45, 
49, 75, which could be partially attributable to our choice of samples and methodology.  
The data regarding RASSF1A methylation is rather controversial, although it has been 
suggested as a useful tool for LCa diagnosis49, 62, 76, 77, associations between RASSF1A 
methylation level and poor prognostics 49, 78, 79, were also reported, contrarily to our 
observations. However, Drilon et al.72 demonstrated that RASSF1A promoter methylation 
was not prognostic for early tumor recurrence in their study with resected NSCLC. 
Similarly to our results, an association between gene hypermethylation and poorly 
differentiated histology, was also demonstrated. 
Thus, APC, RASSF1A, RARβ2 and HOXA9 promoter methylation levels are not 
independently indicative of more clinically aggressive LCa, because that is dependent of 
tumor differentiation. 
This exploratory study aimed to differentiate LCa subtypes with a panel of six 
hypermethylated genes, and evaluate the prognostic value of those molecular alterations. 
Thus far no other study has attempted the same, which might explain lack of studies to 
compare our results. Importantly, the most promising candidate biomarkers might be 
tested in cell free DNA from plasma samples of individuals suspected of carrying LCa. 
Such test might not only speed-up the diagnostic process but also help discriminate the 
LCa subtype to assist in clinical decision-making. 
 
 
 
 
 
 
 
 
 
6. CONCLUSIONS AND FUTURE 
PERSPECTIVES
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In conclusion, the evaluation of RARβ2 and HOXA9 promoter methylation levels using 
qMSP appears to be useful to discriminate among major and minor LCa subtypes in FFPE 
tissues. High APC, HOXA9, RARβ2 and RASSF1A promoter methylation levels associate 
with poor disease specific survival owing to its association with tumor differentiation. The 
same holds true for high RASSF1A promoter methylation levels and poor disease free 
survival. The clinical usefulness of these results requires validation in a set of plasma 
samples in the near future. Additional studies are necessary to optimize the ability to 
discriminate LCa subtypes using RARβ2 and HOXA9 promoter methylation levels. 
Validation in plasma it is an important aim because a sensitive detection method could 
enable early diagnosis and improve survival of LCa patients. It is believed that plasma 
DNA is of tumor origin because the genetic alterations are similar to those found in the 
corresponding primary tumors80. Furthermore, many investigators have reported that 
microsatellite alterations and gene mutations could be identified in the plasma DNA of 
various cancer patients, which must derive from cancer cells. Thus, circulating tumor-
derived DNA might be used as a source for tumor detection76, and  quantification of cell-
free DNA in plasma and characterization of specific molecular changes could be very 
useful for the management of LCa80.  
The major advantage of plasma is that it may be used as minimally invasive approach 
for early diagnosis and screening80. However, plasma samples are more challenging, as 
the total amount of lung-derived DNA and the fraction of tumor DNA are expected to be 
significantly lower, moreover, it is reported that sensitivity and specificity are slightly lower 
when using plasma compared e.g. with bronchial aspirates. Furthermore, blood plasma 
contains a complex mixture of DNA originating potentially from any part of the body. 
Hence, the analytical performance requirements for analyzing these body fluids are higher 
and the markers need to be specific for lung tumor DNA to assure a high specificity of the 
test54. 
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APPENDIX I 
DNA Extraction From Formalin-fixed Paraffin-embedded Tissues 
 
From each case, a representative paraffin block was selected and an experienced 
pathologist delimited the area of tumor to be macrodissected. A set of 12 serial tissue 
sections, with 8μm of thickness, were cut from corresponding paraffin block and placed on 
glass slides. A disposable sterile scalpel blade was used to macrodissect the tumor areas 
which were subsequently placed in labeled 1,5mL tubes. 
 Tissue samples were then desparaffinized using Xilol and Ethanol 100%, 90%, 
70% and 50%, and digested in 1000μL of digestion buffer, composed by Tris-HCl 1M, 
EDTA 0,1M, Tween 20 and sterile bidistilled water (B.Braun, Melsungen, Germany), plus 
proteinase K (20mg/ml, 60μL) (Sigma-Aldrich®, Germany), by incubation for 1 to 2 days in 
a water-bath at 55⁰C, until total digestion was accomplished. 
DNA was extracted from tissues samples by the standard phenolchloroform 
procedure, using 500 μL of phenol-chloroform solution at pH 8 (Sigma-Aldrich®, 
Germany; Merck, Germany) in Phase Lock Gel Light tubes (5 PRIME, Germany). After 
centrifuging the tubes for 15 min at 13,000rpm, the upper aqueous phase containing DNA 
was transferred to a new tube, and then precipitated at -20⁰C overnight using chilled 
Ethanol 100% (2 volumes of original amount of this phase), Ammonium Acetate 7,5M (1/3 
volume) (Sigma-Aldrich®, Germany) and glycogen (2μL).  
Posteriorly, samples were washed in ethanol 70%, the pellets air dried and then eluted in 
10 μL of sterile distilled water. DNA concentration and purity were assessed using 
NanoDrop Lite Spectrophotometer (Nanodrop Technologies, USA) and stored at -20°C 
until further use. 
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APPENDIX II 
Bisulfite Treatment of DNA 
Bisulfite treatment of DNA samples was performed using EZ DNA methylation – 
Gold kit (Zymo Research, Orange, CA) after extraction and quantification of DNA. 
Before beginning the procedure, we have to calculate the DNA volume that we will 
use, accordingly to its concentration and the quantity that we want to have (1000ng), and 
then we have to add sterile distilled water to the calculated DNA volume of each sample, 
until we reach the final volume of 20μL.  
To each tube was added 130 µL of CT Conversion Reagent and then incubated in 
a GeneAmp PCR System 2700 thermal cycler (Applied Biosystems, USA) at 98°C for 10 
minutes and then at 64°C for 3 cycles of 60 minutes each. 
Once finished the incubation, samples were transferred to a Zymo-Spin IC column 
with 600 μL of M-binding buffer and centrifuged at 10,000 rpm for 30 seconds. After being 
washed with 100μL of M-Wash buffer and again centrifuged at 10,000 rpm for 30 
seconds, desulphonation was achieved with an incubation at room temperature with 200 
μL of M-Desulphonation buffer for 20 minutes. 
After the incubation, the columns were centrifuged at 10,000 rpm for 30 seconds 
followed by two washing steps with 200 µL of M-Wash buffer and centrifugations at 
10,000 rpm for 30 seconds.  
Finally, the column was removed from the collection tube and placed in a 1.5 mL 
tube. The modified DNA was eluted by incubating the column with 30 µL of sterile distilled 
water for 5 minutes at room temperature followed by a centrifugation at 12,000 rpm for 30 
seconds. This last step was repeated allowing a final volume of 60 µL of modified DNA for 
each sample. The modified DNA was stored at -80°C until further use. 
CpGenomeTM Universal Methylated DNA (Merck Millipore, Germany) was also 
modified, using the guidelines described above and eluted in a total of 20 µL of sterile 
distilled water. 
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APPENDIX III 
 
Figure 20 - Boxplots of (A) SHOX2 and (B) TFPI2 promoter methylation levels between Lung Cancer (LCa) 
and normal lung (NL) samples. 
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APPENDIX IV 
 
Figure 21 - Boxplots of (A) SHOX2 and (B) TFPI2 promoter methylation levels between the major subtypes of 
Lung Cancer (LCa) samples. (NSCLC: Non-small cell lung cancer) 
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Figure 22 - Boxplots of (A) SHOX2 and (B) TFPI2 promoter methylation levels between subtypes of Lung 
Cancer (LCa) samples. (SCC: Squamous cell carcinoma; Ade: Adenocarcinoma; LCC: Large cell carcinoma; 
SCLC: Small cell lung cancer) 
 
 
